Esperion Therapeutics Stock News

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US an

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.81 per share a year ago.

Are you trading penny stocks this week? Chances are that if you're reading this article, you have some intention of finding more info on cheap stocks.

Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigation poses a significant weight on Esperion's stock

If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.05 per share a year ago.

ANN ARBOR, Mich., July 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023.

ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association's 83rd Scientific Sessio

Penny stocks to buy according to 7 insiders in May 2023. The post 7 Hot Penny Stocks To Buy In May According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Penny stocks to buy according to 3 insiders in May 2023. The post 3 Hot Penny Stocks To Buy In May According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock